Alex Friedlaender1, Giulio Metro2, Diego Signorelli3, Alessio Gili4, Panagiota Economopoulou5, Fausto Roila2, Giuseppe Banna6, Alessandro De Toma3, Andrea Camerini7, Athina Christopoulou8, Giuseppe Lo Russo3, Marco Banini2, Domenico Galetta9, Beatriz Jimenez10, Ana Collazo-Lorduy10, Antonio Calles11, Panagiotis Baxevanos12, Helena Linardou13, Paris Kosmidis14, Giannis Mountzios15, Marina C Garassino3, Alfredo Addeo1. 1. Department of Oncology, Geneva University Hospital, Geneva, Switzerland. 2. Santa Maria della Misericordia Hospital, Azienda Ospedaliera di Perugia, Perugia, Italy. 3. Medical Oncology Department, Fondazione IRCCS, Istituto Nazionale Tumori di Milano, Milano, Italy. 4. Public Health Section, Department of Experimental Medicine, University of Perugia, Perugia, Italy. 5. Oncology Department, Attikon University Hospital, Athens, Greece. 6. Medical Oncology, Ospedale Cannizzaro, Catania, Italy. 7. U.O.C. Oncologia, Ospedale Versilia, Lido di Camaiore (LU), Italy. 8. Medical Oncology, Agios Andreas General Hospital of Patras, Patras, Greece. 9. Medical Thoracic Oncology Unit, IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy. 10. Medical Oncology, Hospital Universitario HM Sanchinarro, Madrid, Spain. 11. Division of Medical Oncology, Hospital General Universitario Gregorio Marañón, Madrid, Spain. 12. Second Department of Medical Oncology, Saint Savvas Anti-Cancer Hospital, Athens, Greece. 13. First Department of Medical Oncology, Metropolitan Hospital, Athens, Greece. 14. Second Department of Medical Oncology, Hygeia Hospital, Athens, Greece. 15. Second Department of Medical Oncology, Henry Dunant Hospital Center, Athens, Greece.
Abstract
Objectives: We retrospectively analysed patients with advanced non-small-cell lung cancer (NSCLC) harbouring high PD-L1 expression (>50%) and treated with front-line pembrolizumab, comparing outcomes of patients with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) 2 to those with PS 0-1. Methods: Data were collected by 16 participating centres. All patients with NSCLC and high PD-L1, treated with first-line pembrolizumab were included. We collected medical data from patient files, pathology and laboratory reports. Patient characteristics, comorbidities, PS, and tumour characteristics were reported. Overall survival (OS), progression-free survival (PFS) and response rate (RR) were calculated. Results: 302 patients were included, 246 with PS 0-1, 56 with PS 2. RR was 72% among patients with PS 0-1 compared to 45% with PS2 (odds ratio (OR) 0.31 (95% CI: 0.17-0.57), p < .001). Median PFS was 2.6 months (95% CI: 1.9-5.1) among patients with PS2 and 11.3 months (95% CI: 8.5-14.4) among those with PS 0-1. Median OS was 7.8 months (95% CI: 2.5-10.7) in the PS2 group, not reached in the PS 0-1 group. PS 2 remained predictive of poor outcomes in multivariate analysis. Conclusion: PS 2 is a strong independent predictor of poor response and survival in NSCLC patients with high PD-L1, treated with front-line pembrolizumab. Prospective randomised trials comparing immunotherapy to chemotherapy in this population would be welcome.
Objectives: We retrospectively analysed patients with advanced non-small-cell lung cancer (NSCLC) harbouring high PD-L1 expression (>50%) and treated with front-line pembrolizumab, comparing outcomes of patients with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) 2 to those with PS 0-1. Methods: Data were collected by 16 participating centres. All patients with NSCLC and high PD-L1, treated with first-line pembrolizumab were included. We collected medical data from patient files, pathology and laboratory reports. Patient characteristics, comorbidities, PS, and tumour characteristics were reported. Overall survival (OS), progression-free survival (PFS) and response rate (RR) were calculated. Results: 302 patients were included, 246 with PS 0-1, 56 with PS 2. RR was 72% among patients with PS 0-1 compared to 45% with PS2 (odds ratio (OR) 0.31 (95% CI: 0.17-0.57), p < .001). Median PFS was 2.6 months (95% CI: 1.9-5.1) among patients with PS2 and 11.3 months (95% CI: 8.5-14.4) among those with PS 0-1. Median OS was 7.8 months (95% CI: 2.5-10.7) in the PS2 group, not reached in the PS 0-1 group. PS 2 remained predictive of poor outcomes in multivariate analysis. Conclusion:PS 2 is a strong independent predictor of poor response and survival in NSCLCpatients with high PD-L1, treated with front-line pembrolizumab. Prospective randomised trials comparing immunotherapy to chemotherapy in this population would be welcome.
Authors: Kartik Sehgal; Ritu R Gill; Page Widick; Poorva Bindal; Danielle C McDonald; Meghan Shea; Deepa Rangachari; Daniel B Costa Journal: JAMA Netw Open Date: 2021-02-01
Authors: Alessio Cortellini; Alfredo Addeo; Giuseppe L Banna; Marcello Tiseo; Diego L Cortinovis; Francesco Facchinetti; Joachim G J V Aerts; Cinzia Baldessari; Raffaele Giusti; Emilio Bria; Francesco Grossi; Rossana Berardi; Alessandro Morabito; Annamaria Catino; Carlo Genova; Francesca Mazzoni; Alain Gelibter; Francesca Rastelli; Marianna Macerelli; Rita Chiari; Stefania Gori; Giovanni Mansueto; Fabrizio Citarella; Luca Cantini; Erika Rijavec; Federica Bertolini; Federico Cappuzzo; Alessandro De Toma; Alex Friedlaender; Giulio Metro; Maria Vittoria Pensieri; Giampiero Porzio; Corrado Ficorella; David J Pinato Journal: Thorac Cancer Date: 2021-12-22 Impact factor: 3.223